Table 1

Demographics of the patients and frequency of stroke-like episodes

Patient numberAgeGenderTaurine dose
(g/day)
Mitochondrial DNA mutationHeteroplasmy in peripheral blood leucocytes
(%)
Pretrial period frequency of stroke-like episodes per year*Evaluation period† frequency of stroke-like episodes per yearPercentage reduction of stroke-like episodes by taurine treatment
146F93243A>G28.72.260100
245M123243A>G29.51.561.2032.8
330F123243A>G43.43.670100
419M123243A>G531.341.1712.5
515M93243A>G65.82.670100
631M123271T>C30.92.010100
730F93243A>GNT††2.010100
814M93243A>G57.82.671.2154.7
938M123243A>G21.51.340100
1023M123243A>G39.42.671.2553.4
  • *Stroke-like episodes in the pretrial period were not necessarily confirmed by MRI.

  • †The first 8 weeks after the start of the study drug administration were not included in the evaluation period.

  • †† not tested.